Abstract

OBJECTIVE:

To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity.

DESIGN:

Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress.

SETTING:

Exercise physiology laboratory in a single clinical research center.

Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia